Meeting
2016 ASCO Quality Care Symposium
Comparative effectiveness research in renal cell carcinoma: Lenvatinib with everolimus as a potential new treatment option.
Authors
Gabriel Tremblay
Eisai, Woodcliff Lake, NJ
Gabriel Tremblay, Unnati Majethia, Anna Forsythe, Corey Pelletier
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Practice of Quality and Cost, Value, and Policy in Quality
Track
Cost, Value, and Policy in Quality,Practice of Quality,Science of Quality
Sub Track
Measuring Value and Costs
Citation
J Clin Oncol 34, 2016 (suppl 7S; abstr 27)
DOI
10.1200/jco.2016.34.7_suppl.27
Abstract #
27
Poster Bd #
C12
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
Cabozantinib (Cabo) beyond progression improves survival in advanced renal cell carcinoma patients: The CABEYOND study (Meet-Uro 21).
First Author: Giuseppe Procopio
Poster
2023 ASCO Genitourinary Cancers Symposium
The survival outcomes of metastatic non-clear cell renal cell carcinoma in the immunotherapy era: Princess Margaret Cancer Centre (PMCC) experience.
First Author: Esmail Mutahar Al-Ezzi
Poster
2019 ASCO Annual Meeting
Clinical and economic outcomes associated with sequential treatment in patients with advanced renal cell carcinoma (aRCC).
First Author: Meredith M. Regan
Poster
2019 Genitourinary Cancers Symposium
Prognostic and predictive role of comprehensive geriatric assessment (CGA) in elderly patients with metastatic renal cell cancer (RCC) treated with sunitinib (SUN) or pazopanib (PAZ): A single center experience.
First Author: Francesco Pierantoni